Download MendeleyDiscovery of Phenylacylpiperidine as Novel sEH Inhibitors through Scaffold Hopping of Natural Stilbene.
Ding, J., Zhu, M.Z., Du, X.Y., Liu, S.M., Wang, H., Liu, X.Z., Xie, W.S., Ma, H.L., Feng, Y., Zhu, X.H., Liang, J.H.(2025) J Med Chem 68: 8980-9013
- PubMed: 40227865
- DOI: https://doi.org/10.1021/acs.jmedchem.5c00685
- Primary Citation of Related Structures:
9KPI - PubMed Abstract:
Despite the development of soluble epoxide hydrolase (sEH) inhibitors as a promising therapeutic approach, no drug candidate has successfully progressed beyond clinical phase II, highlighting the need for a novel chemotype with improved in vivo potency, pharmacokinetics and safety. In this study, we discovered a phenylacetylpiperidine-based compound, 77 (lab code: DJ-89 ; IC 50 : 0.51 nM), through strategic scaffold hopping from previously reported styrene-based sEH inhibitors. Resolving the cocrystal structure and mode-of-action studies revealed a distinct profile compared to well-known sEH inhibitors TPPU and EC5026 (IC 50 : 44, 19 nM). Notably, 77 demonstrated additional interactions with sEH compared to TPPU , and uniquely enhanced anti-inflammatory factors, including EET levels and IL-10, a capability not observed with EC5026 . Moreover, 77 showed excellent pharmacokinetics and safety, positioning it as a promising candidate for treating both acute and chronic inflammatory diseases, including rheumatoid arthritis, leveraging phenylacylpiperidine scaffolds in sEH-targeted therapies.
- Key Laboratory of Medicinal Molecule Science and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 102488, China.
Organizational Affiliation:
